Reduces gap between resting potential and threshold
Results in reduced cardiac excitability paradoxically
Slows conduction velocity
QRS prolongation and arrhythmia
Rate of K+ rise matters as much as absolute level
Patients with chronically elevated K+ may have partial adaptation
Therapeutic Considerations
Rationale for three-tier approach
Tier 1 protects the heart but does not lower K+
Calcium buys 30-60 minutes only
All three tiers must be initiated simultaneously in severe cases
Tier 2 provides temporary shift — not elimination
Without Tier 3, K+ will rebound within 4-6 hours
Shift therapies critical for time while elimination begins
Tier 3 is the only definitive treatment
Renal excretion preferred when feasible
Dialysis for oliguric-anuric patients
Newer potassium binders vs SPS
Sodium zirconium cyclosilicate (Lokelma)
FDA approved 2018
Phase III HARMONIZE trial: K+ lowering in 48 hours
Faster onset than patiromer (1-2 hours vs 7 hours)
Patiromer
FDA approved 2015
OPAL-HK trial: enabled continued RAAS inhibitor therapy in CKD-HF
Better suited for chronic management
Both preferred over SPS due to safety and efficacy profile
RAAS inhibitor continuation debate
Discontinuing RAAS inhibitors trades reduced hyperkalemia for increased CV and renal risk
RAAS inhibitors provide mortality benefit in HF and diabetic CKD
KDIGO 2024 guideline: use potassium binders to maintain RAAS inhibitors
Dietary modification enables RAAS inhibitor continuation in many cases
Reduction in nonplant potassium sources more impactful than blanket restriction
Plant-based K+ lower bioavailability
Monitoring strategy after treatment
Shift therapies (insulin, albuterol): effect begins 15-30 min, peaks 60 min
Repeat K+ at 1-2 hours
Elimination therapies: effect over hours
Repeat K+ at 4-6 hours
Rebound hyperkalemia common if source not eliminated
Serial K+ every 4-6 hours until stable
Patient Discharge Instructions
copy discharge instructions
Discharge instructions for Hyperkalemia
Your potassium level was found to be too high (hyperkalemia). High potassium can be dangerous for your heart and muscles. You have been treated and your potassium level is now in a safer range. It is important to follow these instructions carefully to prevent it from rising again.
Medications
Take all medications exactly as prescribed
Do NOT restart the following medications until cleared by your doctor
Any ACE inhibitor or ARB blood pressure medications (if held)
Any potassium-sparing water pills (spironolactone, amiloride)
Mitchell SH, Brady WJ. In: The Electrocardiogram in Emergency and Acute Care. 2023.
ECG staging and progression framework
Controversies in Management of Hyperkalemia 2018
Long B, Warix JR, Koyfman A. J Emerg Med. 2018.
Evidence review of shift and elimination therapies
Tumor Lysis Syndrome Guidelines 2008
Coiffier B et al. J Clin Oncol. 2008.
Cairo-Bishop laboratory and clinical TLS criteria
Abnormalities of Potassium in Heart Failure: JACC State-of-the-Art Review 2020
Ferreira JP et al. J Am Coll Cardiol. 2020.
Heart failure-specific hyperkalemia management
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.